GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Globus Medical Inc (NYSE:GMED) » Definitions » ROE %

Globus Medical (Globus Medical) ROE % : 1.47% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Globus Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Globus Medical's annualized net income for the quarter that ended in Dec. 2023 was $60 Mil. Globus Medical's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $4,093 Mil. Therefore, Globus Medical's annualized ROE % for the quarter that ended in Dec. 2023 was 1.47%.

The historical rank and industry rank for Globus Medical's ROE % or its related term are showing as below:

GMED' s ROE % Range Over the Past 10 Years
Min: 4.2   Med: 11.96   Max: 17.49
Current: 4.41

During the past 13 years, Globus Medical's highest ROE % was 17.49%. The lowest was 4.20%. And the median was 11.96%.

GMED's ROE % is ranked better than
57.95% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.29 vs GMED: 4.41

Globus Medical ROE % Historical Data

The historical data trend for Globus Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Globus Medical ROE % Chart

Globus Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.99 7.03 9.19 10.60 4.20

Globus Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.09 10.45 11.84 0.13 1.47

Competitive Comparison of Globus Medical's ROE %

For the Medical Devices subindustry, Globus Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Globus Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Globus Medical's ROE % falls into.



Globus Medical ROE % Calculation

Globus Medical's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=122.873/( (1846.373+3997.959)/ 2 )
=122.873/2922.166
=4.20 %

Globus Medical's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=60.136/( (4187.285+3997.959)/ 2 )
=60.136/4092.622
=1.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Globus Medical  (NYSE:GMED) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=60.136/4092.622
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(60.136 / 2466.136)*(2466.136 / 5220.979)*(5220.979 / 4092.622)
=Net Margin %*Asset Turnover*Equity Multiplier
=2.44 %*0.4724*1.2757
=ROA %*Equity Multiplier
=1.15 %*1.2757
=1.47 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=60.136/4092.622
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (60.136 / 99.976) * (99.976 / 103.816) * (103.816 / 2466.136) * (2466.136 / 5220.979) * (5220.979 / 4092.622)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6015 * 0.963 * 4.21 % * 0.4724 * 1.2757
=1.47 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Globus Medical ROE % Related Terms

Thank you for viewing the detailed overview of Globus Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Globus Medical (Globus Medical) Business Description

Traded in Other Exchanges
Address
2560 General Armistead Avenue, Audubon, PA, USA, 19403
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
Executives
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Dan Wolterman director 3721 VALLEY CENTRE DR, SUITE 500, SAN DIEGO CA 92130
John A Deford director C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Dan Lemaitre director 2 MUSICK, IRVINE CA 92618
Keith W Pfeil officer: SVP, Chief Financial Officer GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Kelly Huller officer: SVP, General Counsel 2560 GENERAL ARMISTEAD AVENUE, AUDOBON PA 19403
David D Davidar director, officer: Vice President, Operations C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Daniel T Scavilla officer: Senior VP and CFO C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
David M Demski director, officer: President and COO C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert Andrew Douglas director 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Stephen T Zarrilli director FIBERLINK COMMUNICATIONS CORP., 794 PENLLYN PIKE, BLUE BELL PA 19422
Anthony L Williams officer: Senior VP of Bus. Devel. & GC C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Steven Payne officer: Chief Accounting Officer C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
David C Paul director, 10 percent owner, officer: Chief Executive Officer C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403